X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (61) 61
Publication (8) 8
Book / eBook (6) 6
Conference Proceeding (5) 5
Dissertation (3) 3
Patent (3) 3
Book Chapter (2) 2
Magazine Article (2) 2
Book Review (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (37) 37
humans (29) 29
female (26) 26
male (23) 23
middle aged (20) 20
aged (17) 17
adult (14) 14
surgery (14) 14
abridged index medicus (10) 10
cardiac & cardiovascular systems (9) 9
risk (9) 9
treatment outcome (8) 8
young adult (8) 8
aged, 80 and over (7) 7
survival (7) 7
time factors (7) 7
adolescent (6) 6
animals (6) 6
guidelines (6) 6
mortality (6) 6
prosthesis design (6) 6
reoperation (6) 6
retrospective studies (6) 6
bioprosthesis (5) 5
cancer (5) 5
experience (5) 5
heart valve prosthesis (5) 5
influenza (5) 5
kaplan-meier estimate (5) 5
respiratory system (5) 5
risk factors (5) 5
transplantation (5) 5
age (4) 4
aortic valve - surgery (4) 4
article (4) 4
atrial fibrillation (4) 4
atrial fibrillation - complications (4) 4
carboplatin (4) 4
cardiology and cardiovascular medicine (4) 4
cardiothoracic surgery (4) 4
chemotherapy (4) 4
clinical medicine (4) 4
clinical trials (4) 4
disease-free survival (4) 4
follow-up studies (4) 4
glaucoma (4) 4
health risk assessment (4) 4
heart valve diseases - surgery (4) 4
heart valve prosthesis implantation - adverse effects (4) 4
heart valve prosthesis implantation - instrumentation (4) 4
life sciences (4) 4
management (4) 4
optical coherence tomography (4) 4
ovarian cancer (4) 4
paclitaxel (4) 4
patients (4) 4
position (4) 4
prosthesis (4) 4
rats (4) 4
replacement (4) 4
retina (4) 4
stroke - etiology (4) 4
survival analysis (4) 4
womens health (4) 4
[ math ] mathematics [math] (3) 3
adults (3) 3
age factors (3) 3
analysis (3) 3
antineoplastic combined chemotherapy protocols - adverse effects (3) 3
antineoplastic combined chemotherapy protocols - therapeutic use (3) 3
bevacizumab (3) 3
blasting (3) 3
carboplatin - administration & dosage (3) 3
cardiovascular (3) 3
cells, cultured (3) 3
child (3) 3
child, preschool (3) 3
children (3) 3
combustion apparatus (3) 3
combustion processes (3) 3
computational anatomy (3) 3
confidence intervals (3) 3
details of domestic stoves or ranges, of general application (3) 3
double-blind method (3) 3
epidemiology (3) 3
health aspects (3) 3
heart valve diseases - mortality (3) 3
heart valve prosthesis implantation - mortality (3) 3
heating (3) 3
hematology (3) 3
hematology, oncology and palliative medicine (3) 3
hospital mortality (3) 3
hospitals (3) 3
iii trial (3) 3
immunization (3) 3
immunohistochemistry (3) 3
influenza vaccines (3) 3
internal medicine (3) 3
journal article (3) 3
klinisk medicin (3) 3
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 1, pp. 78 - 89
Summary Background Angiogenesis is a target in the treatment of ovarian cancer. Nintedanib, an oral triple angiokinase inhibitor of VEGF receptor,... 
Hematology, Oncology and Palliative Medicine | BIBF 1120 | DES CANCERS | INTERGROUP TRIAL | LABEL DOSE-ESCALATION | CISPLATIN | ONCOLOGY | BEVACIZUMAB | TRIPLE ANGIOKINASE INHIBITOR | CARBOPLATIN PLUS PACLITAXEL | III TRIAL | MAINTENANCE THERAPY | Humans | Middle Aged | Ovarian Neoplasms - pathology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Response Evaluation Criteria in Solid Tumors | Diarrhea - chemically induced | Cytoreduction Surgical Procedures | Indoles - administration & dosage | Young Adult | Peritoneal Neoplasms - drug therapy | Aged, 80 and over | Adult | Female | Carcinoma - pathology | Neutropenia - chemically induced | Paclitaxel - administration & dosage | Ovarian Neoplasms - drug therapy | Fallopian Tube Neoplasms - drug therapy | Carcinoma - drug therapy | Peritoneal Neoplasms - pathology | Double-Blind Method | Carcinoma - surgery | Peritoneal Neoplasms - surgery | Anemia - chemically induced | Carboplatin - administration & dosage | Fallopian Tube Neoplasms - pathology | Thrombocytopenia - chemically induced | Disease Progression | Disease-Free Survival | Indoles - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Fallopian Tube Neoplasms - surgery | Intention to Treat Analysis | Aged | Neoplasm Staging | Ovarian Neoplasms - surgery | Clinical trials | Chemotherapy | Hospitals | Growth factors | Cancer | Ovarian cancer | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Cancer and Oncology | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2011, Volume 365, Issue 26, pp. 2484 - 2496
The addition of bevacizumab to chemotherapy (15 mg/kg for six cycles) followed by extended therapy with bevacizumab every 3 weeks for a total of 15 months of... 
CARBOPLATIN-PACLITAXEL | 1ST-LINE TREATMENT | MEDICINE, GENERAL & INTERNAL | INTERGROUP TRIAL | GYNECOLOGIC-ONCOLOGY-GROUP | SOLID TUMORS | ANGIOGENESIS | CYCLOPHOSPHAMIDE | EXPRESSION | INTRAPERITONEAL CISPLATIN | III TRIAL | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Double-Blind Method | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Carboplatin - administration & dosage | Combined Modality Therapy | Ovarian Neoplasms - mortality | Neoplasms, Glandular and Epithelial - surgery | Bevacizumab | Disease-Free Survival | Neoplasms, Glandular and Epithelial - mortality | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoplasms, Glandular and Epithelial - drug therapy | Survival Analysis | Angiogenesis Inhibitors - therapeutic use | Carcinoma, Ovarian Epithelial | Quality of Life | Female | Paclitaxel - administration & dosage | Angiogenesis Inhibitors - adverse effects | Ovarian Neoplasms - drug therapy | Ovarian Neoplasms - surgery | Drugs | Dose-response relationship (Biochemistry) | Product/Service Evaluations | Drug therapy | Ovarian cancer | Risk groups | Body weight | Clinical trials | Survival | Angiogenesis | Chemotherapy | Womens health | Paclitaxel | Carboplatin | Vascular endothelial growth factor | Cancer | Index Medicus | Abridged Index Medicus
Journal Article
Vaccine, ISSN 0264-410X, 08/2019, Volume 37, Issue 35, pp. 5089 - 5095
Influenza vaccination remains the most effective tool for reducing seasonal influenza disease burden. Few Low and Middle-Income Countries (LMICs) have robust,... 
Influenza, Influenza vaccine, low and middle-income countries | Vaccination programs | NITAG | Vaccine policy | Influenza vaccines | Influenza | Public-private sector cooperation | Immunization | Technical services | Pandemics | Sustainability | Vaccination | Income | Partnerships | Program evaluation | Vaccines | Disease control
Journal Article
Journal Article
Journal Article